{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T03:42:03Z","timestamp":1771990923686,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2002,9,1]],"date-time":"2002-09-01T00:00:00Z","timestamp":1030838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Drug React Toxicol Rev"],"published-print":{"date-parts":[[2002,9]]},"DOI":"10.1007\/bf03256192","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T14:22:37Z","timestamp":1345213357000},"page":"161-166","source":"Crossref","is-referenced-by-count":2,"title":["Adverse Drug Reaction Update"],"prefix":"10.1007","volume":"21","member":"297","published-online":{"date-parts":[[2012,8,15]]},"reference":[{"key":"BF03256192_CR1","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1136\/bmj.324.7349.1287","volume":"324","author":"P. J\u00fcni","year":"2002","unstructured":"J\u00fcni P, Rutjes AWS, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs? BMJ 2002; 324: 1287\u20138","journal-title":"BMJ"},{"key":"BF03256192_CR2","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/bmj.324.7349.1289","volume":"324","author":"M.M. Skelly","year":"2002","unstructured":"Skelly MM, Hawkey CJ. Potential alternatives to COX 2 inhibitors. BMJ 2002; 324: 1289\u201390","journal-title":"BMJ"},{"key":"BF03256192_CR3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.4088\/JCP.v63n0414","volume":"63","author":"A.H. Clayton","year":"2002","unstructured":"Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63: 357\u201366","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"BF03256192_CR4","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002018-200225040-00001","volume":"25","author":"J.P. Orlowski","year":"2002","unstructured":"Orlowski JP, Hanhan UA, Fiallos MR. Is aspirin a cause of Reye\u2019s syndrome?: a case against Is aspirin a cause of Reye\u2019s syndrome?: a case against. Drug Safety 2002; 25 (4): 225\u201331","journal-title":"Drug Safety"},{"key":"BF03256192_CR5","first-page":"766","volume":"43","author":"X. Ma","year":"2002","unstructured":"Ma X, Does M, Buffler PA, et al. Hepatitis B vaccination and the risk of childhood leukemia. 93rd Annual Meeting of the American Association for Cancer Research 2002; 43: 766","journal-title":"93rd Annual Meeting of the American Association for Cancer Research"},{"key":"BF03256192_CR6","volume-title":"Actos and Avandia labeling strengthened to more clearly describe cardiovascular risks [online]","author":"US FoodDrug Administration.","year":"2002","unstructured":"US Food and Drug Administration. Actos and Avandia labeling strengthened to more clearly describe cardiovascular risks [online]. Available from URL: http:\/\/www.fda.gov [Accessed 2002 Apr 19]"},{"key":"BF03256192_CR7","volume-title":"Zyban (bupropion hydrochloride): safety update [online]","author":"Medicines Control Agency.","year":"2002","unstructured":"Medicines Control Agency. Zyban (bupropion hydrochloride): safety update [online]. Available from URL: http:\/\/www.mca.gov.uk [Accessed 2002 Apr 19]"},{"key":"BF03256192_CR8","volume-title":"Kava-containing dietary supplements may be associated with severe liver injury [online]","author":"FoodDrug Administration.","year":"2002","unstructured":"Food and Drug Administration. Kava-containing dietary supplements may be associated with severe liver injury [online]. Available from URL: http:\/\/www.fda.gov [Accessed 2002 Mar 25]"},{"key":"BF03256192_CR9","unstructured":"US Food and Drug Administration. FDA issues Consumer Advisory that kava products may be associated with severe liver injury. Available from URL: http:\/\/www.cfsan.fda.gov [Accessed 2002 Mar 25]"},{"key":"BF03256192_CR10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2002.20.5.1429","volume":"20","author":"P.D. Nathan","year":"2002","unstructured":"Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alfa-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002; 20: 1429\u201330","journal-title":"J Clin Oncol"},{"key":"BF03256192_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1076-7460.2002.00882.x","volume":"11","author":"G.E. Sander","year":"2002","unstructured":"Sander GE, Guillory GS, Giles TD. Noncardiac drugs and QTc interval prolongation: an often unrecognized risk factor for adverse cardiovascular outcomes. Am J Geriatr Cardiol 2002; 11: 197\u2013202","journal-title":"Am J Geriatr Cardiol"}],"container-title":["Adverse Drug Reactions and Toxicological Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03256192\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03256192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T05:23:50Z","timestamp":1558502630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03256192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,9]]},"references-count":11,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2002,9]]}},"alternative-id":["BF03256192"],"URL":"https:\/\/doi.org\/10.1007\/bf03256192","relation":{},"ISSN":["0964-198X"],"issn-type":[{"value":"0964-198X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,9]]}}}